-
Dr. Hongmei Jing: A New Era of Precision Medicine in Lymphoma Treatment
With the rapid advancements in medical technology and deeper insights into the mechanisms of lymphoma, traditional chemotherapy is gradually giving way to a new era of precision-targeted and immunotherapies. Innovative drugs are emerging like bamboo shoots after the rain, offering personalized treatment paths tailored to lymphoma patients. This marks the dawn of a new era…
-
EBMT China’s Voice | Professors Xiaoyan Ke and Kai Hu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year’s conference,…
-
Expert Interview: Professor Chunrui Li Discusses Advancements in CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Multiple Myeloma (MM) is a common hematologic malignancy, and with the emergence of immunotherapy, particularly CAR-T therapy as a revolutionary immunotherapeutic approach, the survival of patients with relapsed/refractory multiple myeloma (R/R MM) has significantly improved. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)…
-
Professor Yuqian Sun: Advances in Salvage Treatment for Primary Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation Graft Failure
Graft failure is a rare but fatal complication following haploidentical allogeneic hematopoietic stem cell transplantation. A second transplant is almost the only salvage measure for transplant failure. However, outcomes from second transplants have generally been poor, as reported in previous literature. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting was held…
-
Efficacy and Safety of Dual-target CAR-T Therapy for Newly Diagnosed High-Risk Multiple Myeloma
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. At this EHA conference, a study (S200) by Professors Juan Du and Jing Lu from Shanghai Changzheng Hospital was selected for an oral presentation. This study explored the efficacy and safety of GC012F…
-
Extraordinary Insights by Professor Xiaofan Zhu on Team’s EHA-Selected Research: Focus on Bone Marrow Failure
From June 13th to 16th, 2024, the 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, the capital of Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from all over the world each year to share and discuss innovative concepts…
-
Efficacy and Safety of Dual-target CAR-T Therapy for Newly Diagnosed High-Risk Multiple Myeloma
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held in Madrid, Spain, from June 13 to 16, 2024. At this EHA conference, a study (S200) by Professors Juan Du and Jing Lu from Shanghai Changzheng Hospital was selected for an oral presentation. This study explored the efficacy and safety of GC012F…
-
ISTH International Perspective | New Technology, Future Competition: Superior Specificity of New Fibrinogen Assay TFT Compared to Traditional Clauss M
The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential international event in the field of thrombosis and haemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world each year, with its profound…
Connecting Medical Expertise through Media